Compare ADMA Biologics Inc (ADMA) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Enphase Energy Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Enphase Energy Inc trades at $41.41 (market cap $5.67B). The key difference: Enphase Energy Inc is far larger — about 2.7× ADMA Biologics Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | ENPH | |
|---|---|---|
Market Cap | $2.13B | $5.67B |
Sector | Health | Technology |
52-Week High | $20.38 | $72.33 |
52-Week Low | $7.60 | $26.12 |
Enterprise Value | $2.20B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ENPH trades at $42.99, down 0.19% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.47, beating expectations, but revenue declined to $1.47B in 2025 from $2.3B in 2023. Recent news highlights its entry into AI data center power standards and new product launches, including IQ9N microinverters.
Outlook is mixed: analyst consensus is a 'Hold' with a $41.61 price target, below the current price. Opportunities include expansion into AI-driven energy solutions, but risks involve revenue volatility, high valuation multiples, and competitive pressures in the solar sector. Net cash flow remains positive but has weakened from prior years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
